Welcome to our dedicated page for Revelation Biosciences news (Ticker: REVB), a resource for investors and traders seeking the latest updates and insights on Revelation Biosciences stock.
Revelation Biosciences, Inc. reports developments as a clinical-stage life sciences company focused on rebalancing inflammation with its proprietary formulation Gemini. Company updates center on Gemini programs for acute kidney injury, chronic kidney disease, prevention of post-surgical infection, and severe burn-related hyperinflammation and infection.
Recurring announcements include clinical data from the PRIME study, FDA interactions tied to the AKI development pathway, advisory and conference activity, quarterly financial results, warrant inducement financings, proxy matters, and capital-structure actions such as reverse stock splits and Nasdaq listing compliance matters.
Revelation Biosciences (NASDAQ:REVB) will participate in the 38th Annual Roth Conference in Dana Point, CA, on March 23–24, 2026. CEO James Rolke and CFO Chester S. Zygmont III will attend, and the company will hold a fireside chat on March 24, 2026 at 2:00 p.m. PT.
The fireside chat will be webcast live and later posted in the Investors section at www.RevBiosciences.com. Investors seeking meetings should contact their Roth representative.
Revelation Biosciences (NASDAQ: REVB) reported financial results for the three and twelve months ended December 31, 2025, and clinical progress on its Gemini program.
Highlights: $10.7M cash at year-end, $6.7M net proceeds from January 2026 warrant inducement, positive PRIME clinical study results, and an FDA agreement on a single adaptive Phase 2/3 study for Gemini. Company expects cash runway into Q1 2027.
Revelation Biosciences (NASDAQ:REVB) will implement a 1-for-4 reverse stock split effective the morning of January 28, 2026. Post-split shares will begin trading that day under the existing symbol REVB and a new CUSIP 76135L804 will apply. The reverse split is intended to increase the share price to regain compliance with The Nasdaq Capital Market's minimum bid continued listing requirement. Proportionate adjustments will be made to warrants, restricted stock units and stock options. Fractional shares resulting from the split will be rounded up to the nearest whole share.
Revelation Biosciences (NASDAQ:REVB) entered a definitive agreement for immediate exercise of outstanding warrants to purchase up to 13,065,000 common shares at a reduced exercise price of $0.86 per share, generating roughly $11 million in gross proceeds. Closing is expected on or about January 26, 2026, subject to customary conditions. In exchange, exercising holders will receive new Class J warrants exercisable into up to 26,130,000 shares at $0.86 per share, exercisable only after stockholder approval and for a five-year term thereafter. The company will file a resale registration on Form S-3 within 20 days of closing.
Revelation Biosciences (NASDAQ:REVB) said it reached agreement with the FDA on an approval pathway for Gemini to treat Acute Kidney Injury (AKI). The agency agreed that a single adaptive Phase 2/3 randomized, double-blind, placebo-controlled study of approximately 300 patients using a clinically relevant composite primary endpoint (death and/or need for dialysis) plus positive data would be sufficient for an NDA. Revelation plans to build trial infrastructure, engage a CRO, assemble scientific advisors, manufacture clinical supply, and work to initiate the study during 2026.
Revelation Biosciences (NASDAQ:REVB) will present additional clinical data from the recently completed PRIME study on Gemini at the International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) in San Diego.
Presented results reportedly show normalization of the hyperinflammatory state in stage 3–4 CKD patients and restoration of immunocompetence. Presenter: Robin Marsden, SVP Biology. Date/time: Sunday, March 29, 2026, 5:30–7:30 PM PT. Location: Manchester Grand Hyatt, San Diego.
Revelation Biosciences (NASDAQ:REVB) announced an inducement equity grant approved January 8, 2026 of 90,000 restricted stock units (RSUs) to a new non-executive employee. The RSUs were granted outside the company's stockholder-approved equity incentive plan as an inducement under Nasdaq Listing Rule 5635(c)(4). The award vests over two years in equal quarterly installments, beginning on the first quarterly vesting date after the employee's hire date, and is subject to continued service through each vesting date.
Revelation Biosciences (NASDAQ:REVB) announced the initiation of GMP manufacturing for GEMINI and matching placebo to supply later‑stage clinical studies. The manufacturing run will provide clinical drug supply needed to support randomized, double‑blind, placebo‑controlled trials and is described as a critical step toward advancing GEMINI's development and approval pathway.
The company said it is working with a leading global contract manufacturing organization and noted it met with the FDA in December 2025 to seek agency feedback on the clinical development and regulatory pathway for GEMINI as a treatment for acute kidney injury (AKI); Revelation is awaiting the FDA meeting minutes.
Revelation Biosciences (NASDAQ:REVB) announced it has reached a quorum for its Special Meeting on December 3, 2025. Shareholders who have not voted have until 11:59pm ET on December 2, 2025 to submit votes.
The company reaffirmed regulatory progress after successfully submitting and receiving acceptance of an end-of-phase 1 meeting package to FDA on November 20, 2025, and said it remains on track to hold that meeting later in 2025 to discuss the clinical and approval pathway for Gemini for acute kidney injury (AKI). The company also referenced its November 6, 2025 financial report covering the three and nine months ended September 30, 2025, highlighting top-line PRIME clinical results and $9.6 million gross proceeds from a September 2025 warrant inducement.
Revelation Biosciences (NASDAQ:REVB) submitted and had its end-of-phase 1 meeting package accepted by the FDA, and is on track to hold the meeting later in 2025 to get agency feedback on the regulatory pathway for Gemini as a treatment for acute kidney injury (AKI).
The company reported that its Phase 1b PRIME study in stage 3–4 chronic kidney disease met its primary safety and tolerability endpoint and showed reductions in inflammatory activity and restored cellular responses in PBMCs up to 168 hours post-dose. Revelation plans to initiate a later-stage clinical study in 2026 and to publish additional PRIME results while exploring other indications for Gemini.